Europe's Regulators Just Greenlit a Wegovy You Can Swallow

The side effects mirror the injection, too. Nausea, diarrhea, constipation, and vomiting are common, particularly early on during dose escalation. The GI rollercoaster is basically the price of admission for GLP-1 therapy, regardless of how you take it.

And competition is already breathing down Novo's neck. Eli Lilly's orforglipron (Foundayo), a small-molecule oral GLP-1 approved in the U.S. in April 2026, can be taken any time of day, with or without food. Head-to-head data showed it delivered superior weight loss versus oral semaglutide, along with better blood sugar control. When oral Wegovy launches in Europe (expected in the second half of 2026), Lilly won't be far behind.

Still, Novo has a powerful card to play. The Wegovy brand carries cardiovascular outcomes data from the landmark SELECT trial, positioning it not just as a weight-loss drug but as a tool for reducing heart attacks and strokes. That's the kind of evidence that makes European payers, who are notoriously cautious about reimbursing obesity drugs, much more willing to write checks.

A Cancer Drug That Reads the Room

Now for the other approval that flew under the radar. AstraZeneca's Etcamah (camizestrant) is a completely different beast: an oral breast cancer drug, not a metabolic therapy.

Camizestrant is what's called a next-generation SERD (selective estrogen receptor degrader). Think of estrogen receptors as locks on breast cancer cells. Traditional hormone therapies like aromatase inhibitors work by cutting off the key (estrogen). But cancer is clever. Over time, tumors develop mutations in the ESR1 gene that essentially change the lock, letting cancer grow even without the key.

Camizestrant doesn't just block the lock; it destroys it entirely. And it works on both the original and mutated versions. That's a big deal, because ESR1 mutations are one of the most common ways breast cancers escape first-line treatment.

What makes Etcamah's approved use genuinely novel is the timing. The CHMP recommended it for patients who are already on first-line therapy (an aromatase inhibitor plus a CDK4/6 inhibitor) and whose tumors develop an ESR1 mutation, but haven't yet progressed. Doctors detect the mutation through a liquid biopsy (a blood test that catches tumor DNA), then swap the aromatase inhibitor for camizestrant while keeping the CDK4/6 inhibitor going.

It's like changing a tire before it blows out, instead of waiting for the car to crash.

The Data Behind the Switch

The pivotal SERENA-6 trial enrolled 315 patients in this exact scenario. Those who switched to camizestrant saw a 56% reduction in the risk of disease progression or death compared to patients who stayed on their original regimen. Median progression-free survival jumped to roughly 16 months, versus just over 9 months for the control group.

That's a meaningful difference for patients with advanced breast cancer, where buying months of stable disease translates directly into quality of life. Safety was manageable and consistent with what you'd expect from the individual drugs.

It's worth noting that camizestrant hasn't had a smooth ride everywhere. An FDA advisory committee previously raised concerns about the approach, and Etcamah is not yet approved in the United States. Europe, in this case, is moving first.

What This Means for Patients and Markets

These two approvals tell a broader story about where European drug regulation is heading.

For obesity, the arrival of oral Wegovy marks a genuine inflection point. Europe's GLP-1 obesity market has been reimbursement-limited, not demand-limited. Adding a needle-free option could pull in patients who never would have considered an injection, particularly in primary care settings where weekly shots feel like a heavy lift. Novo Nordisk expects first European launches in the second half of 2026, and the company is betting that oral and injectable Wegovy will grow the total market rather than cannibalize each other.

For breast cancer, Etcamah introduces a biomarker-driven, preemptive treatment switch into European oncology. Instead of waiting for scans to show progression, doctors can now act on a blood test. It's precision medicine applied not just to drug selection, but to treatment timing.

Both drugs still need the European Commission's rubber stamp. But barring any surprises, patients across Europe could have access to both within months. A Wegovy you swallow and a breast cancer drug that reads mutations before they matter: not a bad day at the office for the EMA.

$290M Says Your Migraine Drugs Aren't Good Enough

A Paragon Biosciences spinout just raised $290 million to go after migraine prevention with a totally different approach. The bet: current drugs leave half of patients undertreated, and a protein called PACAP could be the missing piece.